Business
Autolus is an early commercial-stage biopharma company commercializing AUCATZYL, obe-cel, for adult relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
Autolus revenue rose sharply with AUCATZYL, but losses, cash burn, equity erosion, and forensic flags stayed severe.
The read at a glance✓ Audited against SEC data
- Business mix — CAR T commercial-stage biopharmaNote
- Revenue — Revenue rose to $75.4MOK
- Losses — Net loss widened to $287.5MWatch
- Cash — FCF fell to -$302.6MWatch
- Balance sheet — Equity fell 58.3%Watch
- Insiders — 0 buys / 0 sellsNote
- Accounting — Altman-Z distress; Beneish flag; EQ greyWatch
Where the revenue comes from
Fiscal 2025, as Autolus Therapeutics plc reports it. History and quarterly detail are in the app.
- Product revenue, net$74.3M
- Technology Options$10.0M
- License$1.1M
Leadership changes
From Autolus Therapeutics plc's own filings, the day they're filed.
- Ryan Richardson · director · appointmenteff. 2025-12-01
- Rob Dolski · principal financial officer · appointmenteff. 2025-04-03
- Andrew Mercieca · President · departureeff. 2025-02-24
Latest filings
- 8-K · Company announcement2026-08-11
- 10-Q · Quarterly report2026-08-11
- 8-K · Company announcement2026-08-03
- 8-K · Company announcement2026-08-03
- 8-K · Company announcement2026-06-29
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Autolus Therapeutics plc, every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.